SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001144204-19-031159
Filing Date
2019-06-17
Accepted
2019-06-17 15:38:38
Documents
2
Group Members
BENJAMIN ROVINSKIDANIEL HETUGERALD BRUNKLUMIRA CAPITAL GP, L.P.LUMIRA CAPITAL II (INTERNATIONAL), L.P.LUMIRA CAPITAL II, L.P.LUMIRA GP HOLDINGS CO.LUMIRA GP INC.PETER VAN DER VELDENVASCO LARCINA

Document Format Files

Seq Description Document Type Size
1 SC 13D tv523620_sc13d.htm SC 13D 246037
2 EXHIBIT 1 tv523620_ex1.htm EX-99.1 16291
  Complete submission text file 0001144204-19-031159.txt   264282
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Subject) CIK: 0001540159 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SC 13D | Act: 34 | File No.: 005-87615 | Film No.: 19901338
SIC: 2834 Pharmaceutical Preparations

Mailing Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5
Business Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 416-213-4223
Lumira Capital Investment Management Inc. (Filed by) CIK: 0001702636 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13D